Benzylpiperidine variations on histamine H3 receptor ligands for improved drug-likeness

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 10, 2014, Pages 2236-2239

  Wingen, Kerstin ^a   Schwed, J Stephan ^b   Isensee, Kathleen ^a   Weizel, Lilia ^a   Živković, Aleksandra ^b   Odazic, Dalibor ^a   Stark, Holger ^b  

^a GOETHE UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antagonists; Drug likeness; GPCR; Lipophilicity

Indexed keywords

BENZYLPIPERIDINE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; JNJ 5207852; PIPERIDINE DERIVATIVE; ST 1032; ST 1703; ST 889; ST 928; UNCLASSIFIED DRUG; 1-BENZYLPIPERIDINE; ANTIHISTAMINIC AGENT; LIGAND; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HYDROPHILICITY; LIGAND BINDING; LIPOPHILICITY; PHYSICAL CHEMISTRY; CHEMISTRY; HUMAN; KINETICS; METABOLISM; SYNTHESIS;

HISTAMINE ANTAGONISTS; HUMANS; KINETICS; LIGANDS; PIPERIDINES; PROTEIN BINDING; RECEPTORS, HISTAMINE H3;

EID: 84899574736     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.03.098     Document Type: Article

References (37)

1. S.J. Hill, C.R. Ganellin, H. Timmerman, J.-C. Schwartz, N.P. Shankley, J.M. Young, W. Schunack, R. Levi, and H.L. Haas Pharmacol. Rev. 49 1997 253
2. E. Tiligada, E. Zampeli, K. Sander, and H. Stark Expert Opin. Invest. Drugs 18 2009 1519
3. M. Walter, T. Kottke, and H. Stark Eur. J. Pharmacol. 668 2011 1
4. K. Sander, T. Kottke, and H. Stark Biol. Pharm. Bull. 31 2008 2163
5. J.D. Brioni, T.A. Esbenshade, T.R. Garrison, and S.R. Bitner J. Pharmacol. Exp. Ther. 336 2011 38
6. R. Leurs, H.F. Vischer, M. Wijtmans, and I.J.P. De Esch Trends Pharmacol. Sci. 32 2011 250
7. M. Walter, and H. Stark Front. Biosci. (Sch. Ed.) S4 2011 461
8. M. Walter, K. Isensee, T. Kottke, X. Ligneau, J.-C. Camelin, J.-C. Schwartz, and H. Stark Bioorg. Med. Chem. Lett. 20 2010 5883
9. K. Sander, Y. von Coburg, J.-C. Camelin, X. Ligneau, O. Rau, M. Schubert-Zsilavech, J.-C. Schwartz, and H. Stark Bioorg. Med. Chem. Lett. 20 2010 1581
10. M. Berlin, C.W. Boyce, and Mde L. Ruiz J. Med. Chem. 54 2011 26
11. K. Isensee, M. Amon, A. Galaparti, X. Ligneau, J.-C. Camelin, M. Capet, J.-C. Schwartz, and H. Stark Bioorg. Med. Chem. Lett. 19 2009 2172
12. T. Miko, X. Ligneau, H.H. Pertz, C.R. Ganellin, J.-C. Schwartz, W. Schunack, and H. Stark J. Med. Chem. 46 2003 1523
13. A.J. Barbier, C. Berridge, C. Dugovic, A.D. Laposky, S.J. Wilson, J. Boggs, L. Aluisio, B. Lord, C. Mazur, C.M. Pudiak, X. Langlois, W. Xiao, R. Apodaca, N.I. Carruthers, and T.W. Lovenberg Br. J. Phamacol. 143 2004 649
14. P. Bonaventure, M. Letavic, C. Dugovic, S. Wilson, L. Alusio, C. Pudiak, B. Lord, C. Mazur, F. Kamme, S. Nishino, N. Carruthers, and T. Lovenberg Biochem. Pharmacol. 73 2007 1084
15. R.J. Gonzales-Rothi, S.A. Zander, and P.R. Ros Chest 107 1995 1763
16. W.H. Halliwell Toxicol. Pathol. 25 1997 53
17. C.A. Dvorak, R. Apocada, A.J. Barbier, C.W. Berridge, S.J. Wilson, J.D. Boggs, W. Xiao, T.W. Lovenberg, and N.I. Carruthers J. Med. Chem. 48 2005 2229
18. A.J. Ratcliffe Curr. Med. Chem. 16 2009 2816
19. A.L. Zulli, L.D. Aimone, J.R. Mathiasen, J.A. Gruner, R. Raddatz, E.R. Bacon, and R.L. Hudkins Bioorg. Med. Chem. Lett. 22 2012 2807
20. N. Levoin, O. Labeeuw, T. Calmels, O. Poupardin-Olivier, I. Berrebi-Bertrand, J.-M. Lecomte, J.-C. Schwartz, and M. Capet Bioorg. Med. Chem. Lett. 21 2011 5378
21. O. Labeeuw, N. Levoin, O. Poupardin-Olivier, T. Calmels, X. Ligneau, I. Berrebi-Bertrand, P. Robert, J.-M. Lecomte, J.-C. Schwartz, and M. Capet Bioorg. Med. Chem. Lett. 21 2011 5384
22. O. Labeeuw, N. Levoin, O. Poupardin-Olivier, T. Calmels, X. Ligneau, I. Berrebi-Bertrand, P. Robert, J.-M. Lecomte, J.-C. Schwartz, and M. Capet Bioorg. Med. Chem. Lett. 23 2013 2548
23. S.V. Selivanova, M. Hiner, F. Combe, K. Isensee, H. Stark, S.D. Krämer, P.A. Schubiger, and S.M. Ametamey Bioorg. Med. Chem. 20 2012 2889
24. G. Meier, J. Apelt, U. Reichert, S. Grassmann, X. Ligneau, S. Elz, F. Leurquin, C.R. Ganellin, J.-C. Schwartz, W. Schunack, and H. Stark Eur. J. Pharm. Sci. 13 2001 249
25. M. Amon, X. Ligneau, J.-C. Camelin, I. Berrebi-Bertrand, J.-C. Schwartz, and H. Stark Chem. Med. Chem. 2 2007 708
26. X. Ligneau, X. Morisset, J. Tardivel-Lacombe, F. Gbahou, C.R. Ganellin, H. Stark, W. Schunack, J.-C. Schwartz, and J.M. Arrang Br. J. Pharmacol. 131 2000 1247
27. T. Kottke, K. Sander, L. Weizel, E.H. Schneider, R. Seifert, and H. Stark Eur. J. Pharmacol. 654 2011 200
28. R. Apodaca, C.A. Dvorak, W. Xiao, A.J. Barbier, J.D. Boggs, S.J. Wilson, T.W. Lovenberg, and N.I. Carruthers J. Med. Chem. 46 2003 3938
29. ChemAxon MarvinSketch 2001.
30. A. Polinsky C.G. Wermuth, The Practice of Medicinal Chemistry 3rd ed. Vol. 19 2008 Elsevier Oxford 244
31. Sander, T. Osiris Property, Explorer 2001.
32. G. Klebe Wirkstoffdesign Entwurf und Entwicklung von Arzneistoffen 2nd ed. Vol. 19 2009 Springer Heidelberg
33. M.D. Shultz Bioorg. Med. Chem. Lett. 23 2013 5980
34. P.D. Leeson, and B. Springthorpe Nat. Rev. Drug Disc. 6 2007 881
35. G.M. Keserü Nat. Rev. Drug Disc. 8 2009 203
36. A.L. Hopkins, G.M. Keserü, P.D. Leeson, D.C. Rees, and C.H. Reynolds Nat. Rev. Drug Disc. 13 2014 105
37. A. Tarcsay, N. Kinga, and G.M. Keserü J. Med. Chem. 55 2012 1252